In addition, subgroup analysis revealed that patients harboring 19‐Del who received EGFR‐TKIs combined with radiotherapy (either for bone metastasis or thoracic radiotherapy) experienced a longer OS duration than those harboring 21‐L858R. This evidence concerns the gene EGFR and bone metastasis.